Uptrend Stocks At Street: Northrop Grumman Corporation (NYSE:NOC), EMC Corporation (NYSE:EMC), ImmunoGen, Inc.'s (NASDAQ:IMGN)

The U.S. Marine Corps has awarded Northrop Grumman Corporation (NYSE:NOC) a $207,291,682 agreement for low-rate early production of AN/TPS-80 Ground/Air Task Oriented Radar systems. Under terms of the agreement with the Marine Corps Program Executive Office for Land Systems, Northrop Grumman will deliver the systems in 2016-17. Further LRIP agreements are estimated, followed by multiyear, full-rate production. Northrop Grumman Corporation (NYSE:NOC) stock hit highest price at $134.26, beginning with a price of $132.10 and reported an increase of 2.61% to the closed at $134.20 with a day range of $131.54-$134.26. The total market capitalization remained 27.108 Billion, total volume of 1.66 Million shares held in the session was surprisingly higher than its average volume of 1063.76 shares.EMC Corporation (NYSE:EMC) released that the purchased of three cloud technology firms. The Cloudscaling Group, Maginatics, and Spanning Cloud Apps; terms not revealed. With today's purchases, EMC broadens its cloud capabilities on three key dimensions. The ability to propose customers hybrid cloud solutions based on OpenStack technology, cloud choice with data mobility across multiple clouds, and new protection capabilities for 'born in the cloud' applications and data. EMC Corporation (NYSE:EMC) stock has highest price of $28.54 in last session, beginning with a price of $28.24 and reported an advance of 0.78% to the closed at $28.48 with a day range of $28.21-$28.54. The stock is going forward its 52-week low with 25.02% and moving down from its 52 week high price with -5.25%.Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) declared that collaboration to develop companion diagnostics for ImmunoGen, Inc.'s (NASDAQ:IMGN) targeted anticancer agents. Ventana Medical Systems, a member of the Roche Group, released it has signed into an contract with ImmunoGen (IMGN) to collaborate on the development of biomarker assays as well as a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates.